Circulation Articles Question Crestor, Stress Statin Selection Complexity
This article was originally published in The Tan Sheet
Executive Summary
Appropriate selection of cholesterol-lowering statins is complicated by determining desirable LDL levels for a patient and comparing side-effect profiles of drugs in the class, an editorial in the May 23 issue of Circulation maintains
You may also be interested in...
AstraZeneca defends Crestor
A Circulation article linking Crestor (rosuvastatin) to a higher risk of muscle and kidney toxicity compared to other statins is misleading and in "direct contrast" to FDA's position, AstraZeneca says May 23. The study by Alawai Alsheikh-Ali, Tufts-New England Medical Center, et al., "attempts to draw conclusions that simply cannot be drawn from adverse event reporting data," the firm says. The findings were released in May (1"The Tan Sheet" May 30, 2005, p. 6)...
AstraZeneca defends Crestor
A Circulation article linking Crestor (rosuvastatin) to a higher risk of muscle and kidney toxicity compared to other statins is misleading and in "direct contrast" to FDA's position, AstraZeneca says May 23. The study by Alawai Alsheikh-Ali, Tufts-New England Medical Center, et al., "attempts to draw conclusions that simply cannot be drawn from adverse event reporting data," the firm says. The findings were released in May (1"The Tan Sheet" May 30, 2005, p. 6)...
AstraZeneca defends Crestor
A Circulation article linking Crestor (rosuvastatin) to a higher risk of muscle and kidney toxicity compared to other statins is misleading and in "direct contrast" to FDA's position, AstraZeneca says May 23. The study by Alawai Alsheikh-Ali, Tufts-New England Medical Center, et al., "attempts to draw conclusions that simply cannot be drawn from adverse event reporting data," the firm says. The findings were released in May (1"The Tan Sheet" May 30, 2005, p. 6)...